RM
Roberto Mignone (Director) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in Teva Pharmaceutical Industries Limited (TEVA). The largest single filing was $14.4M of TEVA (367,600 sh × $39.06, as filed), executed Sep 18. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
4
0 buys · 4 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$18.0M
shares × price, as filed
Last traded
Sep 18
Filed Sep 22
Median ADV $196.1M across their filed names
Open performance→Volume by month
Buys $0
Sells $29.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
TEVARecent filings
TEVASALE
Teva Pharmaceutical Industries Limited
View filing →
$14.4M367,600 sh × $39.06
Exec Sep 18
Filed Sep 22 · 4:21 PM ET TEVASALE Teva Pharmaceutical Industries Limited View filing → $2.3M
77,400 sh × $30.24
Exec Dec 16 2025
Filed Dec 18 2025 · 5:30 PM ET TEVASALE Teva Pharmaceutical Industries Limited View filing → $1.3M
50,000 sh × $26.03
Exec Nov 26 2025
Filed Dec 1 2025 · 5:30 PM ET TEVASALE Teva Pharmaceutical Industries Limited View filing → $4.8M
200,000 sh × $24.11
Exec Nov 6 2025
Filed Nov 10 2025 · 5:30 PM ET TEVASALE Teva Pharmaceutical Industries Limited View filing → $6.3M
286,000 sh × $22.01
Exec Dec 20 2024
Filed Dec 26 2024 · 5:30 PM ET †